Evotec SE (NASDAQ:EVO) Short Interest Down 10.7% in November

Evotec SE (NASDAQ:EVO) saw a significant drop in short interest in November. As of November 30th, there was short interest totalling 401,600 shares, a drop of 10.7% from the November 15th total of 449,700 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 197,200 shares, the days-to-cover ratio is currently 2.0 days.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Evotec in a report on Thursday, November 7th. Jefferies Financial Group cut Evotec from a “buy” rating to a “hold” rating and cut their price target for the company from $8.70 to $3.80 in a research note on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $5.93.

Evotec Stock Performance

Evotec stock traded up $0.11 during trading hours on Tuesday, reaching $4.78. 159,667 shares of the stock were exchanged, compared to its average volume of 132,854. The stock has a 50 day moving average of $4.22 and a two-hundred day moving average of $4.14. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43. Evotec has a twelve month low of $2.85 and a twelve month high of $12.00.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Cetera Advisors LLC acquired a new stake in Evotec in the first quarter valued at about $188,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Evotec in the 2nd quarter valued at approximately $87,000. DCF Advisers LLC grew its holdings in shares of Evotec by 140.5% during the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock valued at $552,000 after purchasing an additional 67,156 shares during the last quarter. Novo Holdings A S acquired a new position in Evotec during the 2nd quarter worth approximately $71,183,000. Finally, Mediolanum International Funds Ltd bought a new position in Evotec in the 3rd quarter valued at approximately $512,000. 5.81% of the stock is owned by institutional investors.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.